US3764679A - Iodinin as an anti-hypertensive agent - Google Patents
Iodinin as an anti-hypertensive agent Download PDFInfo
- Publication number
- US3764679A US3764679A US00236179A US3764679DA US3764679A US 3764679 A US3764679 A US 3764679A US 00236179 A US00236179 A US 00236179A US 3764679D A US3764679D A US 3764679DA US 3764679 A US3764679 A US 3764679A
- Authority
- US
- United States
- Prior art keywords
- iodinin
- hypertensive
- hypertensive agent
- patients
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NBMOVCYIGUDQJE-UHFFFAOYSA-N iodinin Chemical compound C1=CC=C2[N+]([O-])=C3C(O)=CC=CC3=[N+]([O-])C2=C1O NBMOVCYIGUDQJE-UHFFFAOYSA-N 0.000 title abstract description 11
- 239000002220 antihypertensive agent Substances 0.000 title description 5
- 229940030600 antihypertensive agent Drugs 0.000 title description 5
- 238000000034 method Methods 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 230000001631 hypertensive effect Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 2
- 241000906446 Theraps Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Definitions
- This invention relates to a method of reducing blood pressure in hypertensive patients using iodinin as the anti-hypertensive agent.
- lodinin is represented by the formula
- the compound can be prepared according to the method described by U.S. Pat. No. 3,432,505.
- lodinin has previously been reported to be an antibacterial agent (see U.S. Pat. No. 3,432,505). We have unexpectedly found that iodinin is an effective antihypertensive agent.
- lodinin is effective as an anti-hypertensive agent at dosages of from approximately 0.1 to approximately 300 mg./kg. of body weight daily and is administered to hypertensive patients at such dosages, preferably by the oral route in divided dosages i.e., 3 to 4 times daily. It may also be co-administered with, for example, diuretics or tranquilizers.
- the oral LD of iodinin is greater than 1 gram/kg. Therefore, a good therapeutic index of safety is present.
- iodinin can be administered alone, that is, as a sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration, such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like.
- the oral dosage forms are prepared by the methods well known in the art, as are the parenteral and generally include a pharmaceutically acceptable carrier or diluent.
- a method of lowering blood pressure in a hypertensive patient comprising administering a therapeutically effective amount of iodinin to said patient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of reducing blood pressure in hypertensive patients by administering a therapeutically effective amount of iodinin to said patients.
Description
United States Patent [191 Jones et al.
IODININ AS AN ANTl-HYPERTENSIVE AGENT Inventors: Peter Hadley Jones, Lake Forest;
Pitambar Somani, Village of Libertyville, both of III.
Abbott Laboratories, North Chicago, Ill.
Filed: Mar. 20, 1972 Appl. No.: 236,179
Assignee:
US. Cl. 424/250 Int. Cl. A6lk 27/00 Field of Search 424/250 Primary Examiner-Jerome D. Goldberg AttorneyRobert L. Niblack 57 I ABSTRACT A method of reducing blood pressure in hypertensive patients by administering a therapeutically effective amount of iodinin to said patients.
-1 Claim, No Drawings IODININ AS AN ANTI-HYPERTENSIVE AGENT DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method of reducing blood pressure in hypertensive patients using iodinin as the anti-hypertensive agent.
lodinin is represented by the formula The compound can be prepared according to the method described by U.S. Pat. No. 3,432,505.
lodinin has previously been reported to be an antibacterial agent (see U.S. Pat. No. 3,432,505). We have unexpectedly found that iodinin is an effective antihypertensive agent.
The anti-hypertensive activity of iodinin was first established in the spontaneously hypertensive rat procedure, Tabei et al. Clin. Pharmac. and Therap., ll (2): 269-274, (1970).
lodinin is effective as an anti-hypertensive agent at dosages of from approximately 0.1 to approximately 300 mg./kg. of body weight daily and is administered to hypertensive patients at such dosages, preferably by the oral route in divided dosages i.e., 3 to 4 times daily. It may also be co-administered with, for example, diuretics or tranquilizers.
The oral LD of iodinin is greater than 1 gram/kg. Therefore, a good therapeutic index of safety is present.
While iodinin can be administered alone, that is, as a sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration, such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like. The oral dosage forms are prepared by the methods well known in the art, as are the parenteral and generally include a pharmaceutically acceptable carrier or diluent.
We claim:
1. A method of lowering blood pressure in a hypertensive patient comprising administering a therapeutically effective amount of iodinin to said patient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23617972A | 1972-03-20 | 1972-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3764679A true US3764679A (en) | 1973-10-09 |
Family
ID=22888453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US00236179A Expired - Lifetime US3764679A (en) | 1972-03-20 | 1972-03-20 | Iodinin as an anti-hypertensive agent |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3764679A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042894A1 (en) * | 2007-07-13 | 2009-02-12 | Food Industry Research And Development Institute | Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin |
| WO2015063516A2 (en) | 2013-11-01 | 2015-05-07 | Universitetet I Oslo | Compounds |
-
1972
- 1972-03-20 US US00236179A patent/US3764679A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Chemical Abstracts 71: 79596 W (1969). * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042894A1 (en) * | 2007-07-13 | 2009-02-12 | Food Industry Research And Development Institute | Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin |
| WO2015063516A2 (en) | 2013-11-01 | 2015-05-07 | Universitetet I Oslo | Compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| AU601237B2 (en) | The use of paroxetine to treat pain | |
| US4794103A (en) | Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| US3624216A (en) | 8-substituted theophyllines as anti-inflammatory agents | |
| US3885035A (en) | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines | |
| DK167559B1 (en) | BUPRENORPHIC CONTAINED PHARMACEUTICAL SUPPLY | |
| US3764679A (en) | Iodinin as an anti-hypertensive agent | |
| KR100420673B1 (en) | Nasal administration to treat delayed nausea | |
| CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| Devière et al. | Ischemic pancreatitis and hepatitis secondary to ergotamine poisoning | |
| WO1994005300B1 (en) | Use of rapamycin in the treatment of aids | |
| AU630373B2 (en) | Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination | |
| US4298611A (en) | Process for reducing blood pressure in animals | |
| US4122177A (en) | Method of treating oligospermia and asthenospermia | |
| US3895114A (en) | Cyclic hydroxamic acids as antihypertensive agents | |
| US3914425A (en) | Antitussive codeine composition | |
| KR900701301A (en) | Treatment of myelosuppression associated with AIDS | |
| US4663345A (en) | Etodolac for treatment of gout | |
| EP0256629A2 (en) | Tolrestat or a salt thereof as an immuno-stimulating agent | |
| JPS6116A (en) | Improvements related to organic compounds | |
| US4195089A (en) | Synergistic composition for malaria | |
| RU2002108806A (en) | A method for the treatment of autoimmune arthritis in animals | |
| US3806594A (en) | Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium |